Back to search results

Collecting and Studying Samples for Prostate or Bladder/Urothelial Cancer

This study is collecting and studying blood and tissue samples from men with prostate or bladder/urothelial cancer that has either come back in the same area or spread to other parts of the body. You may be eligible if you have localized (in the original area) or metastatic (spread) bladder/urothelial or prostate cancer. The goal is to learn more about how these cancers develop and respond to treatment. By studying these samples, researchers hope to find new ways to identify cancer (biomarkers), discover new targets for drugs, and understand why some treatments stop working. This could lead to better treatments for these cancers in the future.

Study design
This is an observational study, meaning researchers will collect and study samples without providing a specific treatment. It aims to enroll up to 1500 participants.
What's involved
You would provide blood and tissue samples for analysis, including DNA sequencing and gene expression studies.
Compensation
Not stated in the trial record.
Follow-up
The samples will be analyzed for up to 6 years after collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01050504

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Recruiting
Not specifiedAges 18+Observational
University of Washington
~1,500 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:Cytology Specimen Collection ProcedureLaboratory Biomarker Analysis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
DNA genomic sequencing
Measured over Up to 6 years
+2 more outcomes measured

Conditions

Localized Renal Pelvis and Ureter Urothelial Carcinoma
Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Soft Tissues
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Recurrent Bladder Carcinoma
Recurrent Prostate Carcinoma
Recurrent Renal Pelvis and Ureter Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Stage IV Prostate Cancer AJCC v7

Explore related trials

Bladder CarcinomaProstate CarcinomaUrothelial Carcinoma

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Robert B. Montgomery · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Robert B. Montgomery
[email protected]
206-598-0856
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured
Ability to adequately understand and give informed consent
Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study
Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured
Platelet count \> 50,000
White blood cell (WBC) \> 1,500
Hemoglobin (Hgb) \> 8.0
International normalized ratio (INR) \< 1.5
Partial thromboplastin time (PTT) \< 45
No history of excessive unexplained bleeding from previous surgery

Exclusion

Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days
Serious or uncontrolled infection
Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days

What this trial measures

  • DNA genomic sequencingUp to 6 years
  • Gene expression profile using microarray assaysUp to 6 years
  • Mutation mapping using the OncoMap and other genotyping techniquesUp to 6 years